Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety and efficacy of nemolizumab injection in atopic dermatitis (Japan observational study)
jRCT1031240707Active, not recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of nemolizumab in atopic dermatitis (AD) (2 cohorts), sponsored by Maruho Co., Ltd. Primary endpoint: Incidence of generalized skin rash during early and intermediate stages of nemolizumab administration. Started Apr 2025; status: active, not recruiting.
02
Drugs
nemolizumab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT1031240707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031240707.